Prosecution Insights
Last updated: November 04, 2026

Genomicare Biotechnology (Shanghai) Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Genomicare Biotechnology (Shanghai) Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area, where it currently manages 1 pending office action. This action is assigned to 1 distinct examiner, reflecting a concentrated effort in its patent prosecution. The data shows that the portfolio is also limited to 1 distinct art unit, which suggests that the company's current innovations are focused within a narrow technical niche. This structure allows for a very specific legal strategy tailored to the requirements of that single art unit at the USPTO.

The busiest examiner identified in the data is KRIANGCHAIVECH, KETTIP, who is handling the 1 busiest examiner pending office action. As the only examiner currently engaged with the portfolio, KRIANGCHAIVECH, KETTIP is the central figure in determining the success of the company's pending claims. For the practitioner, this means that understanding this examiner's past decisions and preferences is critical. The fact that there is only 1 distinct examiner simplifies the communication process between the applicant and the USPTO.

Having 1 pending office action means the portfolio is in a relatively quiet but critical phase of its development. Since the 1 distinct examiner is also the busiest examiner, the entire immediate future of the portfolio's growth rests on this single interaction. This concentration allows the company to dedicate its full attention to resolving the issues raised in this one action, potentially leading to a more robust and well-defined patent grant for its genomic technology.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KRIANGCHAIVECH, KETTIP 1 18.6% +27.9%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18159923 METHODS FOR PREDICTING SYNERGISTIC DRUG COMBINATION KRIANGCHAIVECH, KETTIP —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18159923 METHODS FOR PREDICTING SYNERGISTIC DRUG COMBINATION KRIANGCHAIVECH, KETTIP —

Top Art Units

Art UnitApps
1686 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18159923 METHODS FOR PREDICTING SYNERGISTIC DRUG COMBINATION KRIANGCHAIVECH, KETTIP 1686 §101§103§112 Non-Final OA — Pending Jan 26, 2023

Managing Genomicare Biotechnology (Shanghai) Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Genomicare Biotechnology (Shanghai) Co. Ltd. have?

Genomicare Biotechnology (Shanghai) Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Genomicare Biotechnology (Shanghai) Co. Ltd. applications?

Kettip Kriangchaivech has the most, with 1 of Genomicare Biotechnology (Shanghai) Co. Ltd.'s pending office actions.

What technology area are Genomicare Biotechnology (Shanghai) Co. Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month